Sunday, 29 March 2020

Generics News

  • AstraZeneca, BMS gets FDA nod for diabetes drug

    Generics |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 09 Jan, 2014

    Singapore: AstraZeneca and Bristol-Myers Squibb have recieved U.S. Food and Drug Administration (FDA) approval for diabetes drug Farxiga (dapagliflozin). AstraZeneca and Bristol-Myers Squi...Read more

  • Ranbaxy advisory: All our products are safe and efficacious

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 03 Jun, 2013

    New Delhi: Ranbaxy issued an advisory claiming that all their products in the Indian and global markets are safe and efficacious. The firm revealed that the advisory was issued in public i...Read more

  • Rabies claims 100 lives annually in Vietnam: UN

    Generics |  Analysis | By BioSpectrum Bureau  | 0 Comment | 30 Sep, 2013

    Singapore: Vietnam has seen a substantial increase in the number of rabies fatalities from 34 deaths in 2003 to 131 deaths in 2007, according to United Nations (UN). World Rabies Day, whic...Read more

  • Now Ranbaxy's Mohali unit under FDA scanner

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 24 Jun, 2013

    Singapore: Merely a month after Indian drug major, Ranbaxy, pleaded guilty of having misled the USFDA investigations, selling adulterated drugs in the US and paying a penalty of $500 millio...Read more

  • Mundipharma, Shionogi tie up for pain treatment in Japan

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 22 Nov, 2013

    Singapore: Mundipharma has entered a license agreement with Japan-based Shionogi for the exclusive rights to develop, manufacture and commercialize the abuse deterrent formulation of Oxycod...Read more

  • GSK files for approval on melanoma drug combo

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 10 Jul, 2013

    Singapore: Britian's leading drug maker, GlaxoSmithKline has filed for US Food and Drug Administration (US FDA) approval for its melanoma drug combo earlier than other competitors. Using d...Read more

  • TB prevention faces gap of $1.6bn: WHO estimates

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2013

    Singapore: WHO and Global Fund to Fight AIDS, TB and Malaria have stressed on strains of tuberculosis with resistance to multiple drugs could spread widely and highlighted an annual need of...Read more

  • Avanir Pharma settles patent litigation with Wockhardt

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 09 Sep, 2013

    Singapore: US based Avanir Pharmaceuticals has entered into a settlement agreement with India's Wockhardt to resolve pending patent litigation in response to Wockhardt's abbreviated new dru...Read more

  • TWi Pharma gets FDA nod for ADHD drug

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 15 May, 2013

    Singapore: Taiwan-based TWi Pharmaceuticals has received tentative approval for its Abbreviated New Drug Application (ANDA) for Guanfacine Hydrochloride extended release tablets 1mg, 2mg, 3...Read more

  • Sandoz launches trial with Amgen biosimilar

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 26 Jun, 2013

    Singapore: The generics unit of Novartis, Sandoz, has launched a late-stage trial with its biosimilar version of Amgen's Enbrel. With this, Novartis has consolidated its leading position in...Read more

  • US company leverages on generics

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2012

    Singapore: US based Par Pharmaceutical has entered into agreements with Watson Pharmaceuticals and Actavis Group to purchase for cash five generic products that are currently marketed in th...Read more

  • NATCO wins compulsory license for anti-cancer drug

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 16 Mar, 2012

    In a landmark decision, Hyderabad-based NATCO Pharma has been granted compulsory license for Sorafenib Tosylate sold under the brand name of Nexavar owned by Bayer. Nexavar is the first-li...Read more

  • Mylan gets FDA nod for Thiamine Hydrochloride Injection

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 02 Jul, 2012

    Singapore: Mylan Institutional business has received final approval from the US Food and Drug Administration (FDA) for Mylan's abbreviated new drug application (ANDA) for preservative-free...Read more

  • Big pharma to drive R&D innovation with $4.4 bn

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 11 Jul, 2013

    Singapore: The European Commission (EC) and other leading pharma giants have come together to invest $4.4 billion into programs that would be focused on innovation in the health sector over...Read more

  • Multiple organzations join hands to curb fake drug business

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2012

    Singapore: US Pharmacopeial Convention (USP) is gearing up its efforts to combat fake medicine circulating in the market and has joined hands with 11 new organizations to strengthen its glo...Read more

  • Arvind sets up $42.37 mn plant top tap US market

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 26 Jun, 2013

    Singapore: Indian pharmaceutical firm, Arvind Remedies has been gearing up to take the US market by storm. The company has invested $42.37 million to set up a new manufacturing facility at ...Read more

  • Lilly strengthens its foothold in China

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 24 Apr, 2012

    Singapore, June 15, 2012:  In support of its commitment to maximize growth opportunities in China, Eli Lilly has plans to increase its network of manufacturing capabilities in the country ...Read more

  • Cipla gets drug pricing breather from Delhi Court

    Generics |  News | By BioSpectrum Bureau  | 0 Comment | 31 Jul, 2013

    Singapore: India's Delhi High Court has extended the operation of its earlier order asking the central government not to take coercive steps against pharma major Cipla. The company was tol...Read more



Podcast

 

Survey Box

Are women in the industry getting the required recognition for their efforts?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls